Lavareze Luccas, Scarini João Figueira, de Lima-Souza Reydson Alcides, Kimura Talita de Carvalho, Gondak Rogério de Oliveira, Egal Erika Said Abu, Altemani Albina, Mariano Fernanda Viviane
Department of Pathology, School of Medical Sciences, State University of Campinas (UNICAMP), São Paulo, Brazil.
Department of Oral Diagnosis, Piracicaba Dental School, State University of Campinas (UNICAMP), Piracicaba, Brazil.
J Oral Pathol Med. 2023 Feb;52(2):101-108. doi: 10.1111/jop.13395. Epub 2023 Jan 9.
In this systematic review, we aimed to evaluate the clinicopathological and prognosis data of patients with salivary gland myoepithelial carcinoma.
MEDLINE/PubMed, Scopus, and Embase search was performed with the keywords "myoepithelial carcinoma" "malignant myoepithelioma," and "salivary glands." Primary salivary glands myoepithelial carcinoma that fulfilled the World Health Organization diagnostic criteria were included. The Joanna Briggs Institute tool was used to assess the risk of bias.
Forty-three studies (71 patients) met the inclusion criteria. The patients showed a mean age of 56.4 ± 19.6 years with no sex predilection. The parotid was the most affected gland (49.3%). The tumor presented as an asymptomatic (65.1%) mass (84%). The most common histological findings were the presence of clear tumor cells (39.7%) and multinodular growth patterns (60.7%). Multivariate analysis showed plasmacytoid cell type (p = 0.010) and solid growth pattern (p = 0.003) were related to decreased disease-free survival. Surgery alone was the most used treatment (53.5%). Patients with a combination of treatments showed a longer disease-free survival (p = 0.049). The 2-year and 5-year overall survival rates were 67.5% and 46.1%, respectively.
Salivary gland myoepithelial carcinoma showed no sex predilection, with a higher incidence in the parotid gland. Cell type, growth pattern, and treatment type may be related to a lower disease-free survival. Overall, salivary gland myoepithelial carcinoma presented low recurrence and metastasis rates. Registration and protocol: This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 checklist and registered in the International Prospective Register of Systematic Reviews (PROSPERO) database (CRD42022311512).
在本系统评价中，我们旨在评估涎腺肌上皮癌患者的临床病理及预后数据。
使用关键词“肌上皮癌”“恶性肌上皮瘤”和“涎腺”在MEDLINE/PubMed、Scopus和Embase数据库进行检索。纳入符合世界卫生组织诊断标准的原发性涎腺肌上皮癌。采用乔安娜·布里格斯研究所工具评估偏倚风险。
43项研究（71例患者）符合纳入标准。患者的平均年龄为56.4±19.6岁，无性别倾向。腮腺是最常受累的腺体（49.3%）。肿瘤表现为无症状肿块（65.1%）（84%）。最常见的组织学表现是存在透明肿瘤细胞（39.7%）和多结节生长模式（60.7%）。多变量分析显示浆细胞样细胞类型（p = 0.010）和实性生长模式（p = 0.003）与无病生存期缩短有关。单纯手术是最常用的治疗方法（53.5%）。联合治疗的患者无病生存期更长（p = 0.049）。2年和5年总生存率分别为67.5%和46.1%。
涎腺肌上皮癌无性别倾向，在腮腺中发病率较高。细胞类型、生长模式和治疗类型可能与较低的无病生存期有关。总体而言，涎腺肌上皮癌的复发和转移率较低。注册与方案：本系统评价遵循系统评价和Meta分析的首选报告项目（PRISMA）2020清单，并在国际前瞻性系统评价注册库（PROSPERO）数据库中注册（CRD42022311512）。
Zotero 插件